Call for emergency action to limit global temperature increases, restore biodiversity, and protect health - The Lancet thelancet.com/journals/lance…

we made it! 🤩✨ Thank you Lexi and Anika Boettcher and everbody else for the huge team effort! And thank you Heiko Lickert, Fabian Theis and Malte Luecken for your support!

We’ve been named a 2021 Fierce 15 #biotech company! Thanks to FierceBiotech for this honor and to our teams at Cellarity and Flagship Pioneering for championing a new approach to #drugdiscovery leveraging the role of the cell in health & disease. bit.ly/3CPtDL7

Beyond semaglutide and tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and make projections out to 52 weeks thelancet.com/journals/lance…

With GLP-1 as your peptide backbone the world of metabolism beckons. LillyDiabetes Former Account of Eli Lilly and Company presents new data for 1) Once weekly oxyntomodulin & 2) The triple GLP1R-GCGR-GIPR agonist in people with #T2D Bariatric surgery-like weight loss with GLP-1 medicines is coming #obesity

GLP-1-steroid family conjugates continue to produce fascinating results in preclinical studies-will they move forward in the clinic? Cell Reports Medicine cell.com/cell-reports-m…

CBMR has secured TWO Novo Nordisk Foundation Ascending Investigator Grants worth DKK 10M (€1.34M) each! 🎉 They go to Assoc Profs Christoffer Clemmensen and @tuomaskilpela to support their research on metabolic health and disease. 🧬🧠🍕💊 For more details, read on!👇 bit.ly/CBMR22_01

A decade after we reported our discovery of the new drug class of dual GLP/GIP agonists, the FDA has now approved the first dual GLP/GIP agonist for the treatment of T2D. A major milestone for the global fight against diabetes & obesity! science.org/doi/10.1126/sc… #Obesity #Diabetes

GLP-1-based therapies are slowly approaching #bariatricsurgery level #weightloss and more exciting science to come. There is the impressive SURMOUNT-1 trial for tirzepatide #obesity nejm.org/doi/full/10.10…

We are looking for talented and enthusiastic scientists (biochemist, islet biologist, stem cell researcher) on all levels of career to join our exciting mission to regenerate beta cells. Helmholtz Munich | @HelmholtzMunich offers an extremely attractive city & environment. RTW and apply to me.

(1/9) New paper out in Translational Psychiatry in which we do a deep dive pre-clinical evaluation of the psychedelic, psilocybin, for obesity treatment. Credit to PhD candidate Nicole Fadahunsi + several lab members for excellent execution. Open access: nature.com/articles/s4139…

Ready, set, code! The Open Problems in Single-Cell Analysis competition at #NeurIPS2022 is open, featuring $25,000 in prizes & a new multimodal #singlecell timecourse deeply profiling hematopoiesis 🥳 🎉🧪🧫 Join us on Kaggle! kaggle.com/competitions/o… To learn more, read on 🧵👇

Insightful summary of the discovery and development of the first generation of efficacious (and safe) drugs for treatment of obesity nature.com/articles/d4158…

💡🔬 How can #transfer be accelerated to bring new ideas from the laboratories to application even faster? Our CEO Matthias Tschöp talks about #startups foundations, overcoming hurdles, and sustaining improvement in transfer activities. 👉Full interview: t1p.de/nfv16

The NK cell receptor NKp46 recognizes ecto-calreticulin on ER-stressed cells | Nature nature.com/articles/s4158…

Online now! Overlooked confounding in studies of metabolite salts dlvr.it/SmRg98

Are we approaching peak #singlecell #islets #diabetes A cross data set roadmap for the understanding of β-cell plasticity, compensation, and demise Heiko Lickert Fabian Theis biorxiv.org/content/10.110…

Incredibly inspiring lecture by Matthias H Tschöp, MD, Helmholtz Zentrum München the Banting Medal for Scientific Achievement awardee. “Overcoming Obesity -The Discovery of Multi Receptor Drugs” #ADA2023

Abata Therapeutics Announces Second Development Candidate, ABA-201, a Novel Treg Cell Therapy for the Treatment of Type 1 Diabetes - Abata Therapeutics abatatx.com/abata-therapeu…